comprehensive -WSS

comprehensive

author：entertainment 2025-09-03 11:50:13 - browse：94681

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

entertainment

WSS

Pediatric cancer treatments threatened by a new FDA policy

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Disappointing trial forces Pfizer to pivot on obesity medicine plans

It was time to plan for my old age. If only I could stop crying

Election results set back Medicaid expansion plans

focus

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Flagship Pioneering launches a new biotech in two countries

After affirmative action ruling, medical educators look to 'holistic review'

Sage considers ways to reduce costs following FDA rejection

Virginia high school admissions case could be legal follow

Sage considers ways to reduce costs following FDA rejection

In Memoriam: Notable people who died in 2023

Rep. Raul Ruiz on the physician shortage and more

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Organ aging and disease risk measured by new blood test

focus

Google's generative AI to analyze medical images — and talk to docs

Rep. Raul Ruiz on the physician shortage and more

CDC director unscathed in first congressional testimony

30 years of 'Listening to Prozac'

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Disappointing trial forces Pfizer to pivot on obesity medicine plans

explore

leisure time

entertainment

hotspot